Antidepressant drugs are the most commonly prescribed class of drugs that is used for the treatment of depression. Depression is a health condition that can affect the normal functioning of an individual's life. Rise in cortisol levels that is triggered by depression results in the enlargement of the amygdala, which is the part of the brain that is responsible for emotional responses. Sleep disturbances, lethargy, suicidal thoughts, etc., can be caused due to this. Therefore, the treatment of depression is of extreme importance for the mental well being of an individual. Drugs are provided on a prescription basis by mental health practitioners in cases with moderate and severe depression. Along with depression, other conditions such as PTSD, OCD, panic disorder, etc., are treated by antidepressants. Fluoxetine, which is commonly sold as Prozac and Sarafem, is a selective serotonin reuptake inhibitor (SSRI) type antidepressant that is used in the treatment of major depressive disorder (MDD), bulimia nervosa, OCD, amongst others. Taken by mouth, Fluxetine has also been used for treating premature ejaculation in young adults. Therefore, the use of antidepressants for the treatment of common disorders, coupled with the rise in depression cases globally that require prescription-based drugs is helping in the growth of the global antidepressant drugs market.

Access the Full Report @ https://www.absolutemarketsinsights.com/reports/Antidepressant-Drugs-Market-2020-%E2%80%93-2028-719

The COVID-19 pandemic has affected countries all over the globe. Studies show that there has been a significant rise in the cases of depression due to the pandemic. Rise in unemployment, coupled with social distancing norms that have reduced the availability of entertainment sources such sporting complexes, can be cited as a major reason for this. Medical professionals are increasingly providing antidepressants to tackle the growth in depression-related cases during the Coronavirus pandemic. Hence, the COVID-19 crisis is expected to have a positive impact on the global antidepressant drugs market in the coming years.

The detailed research study provides qualitative and quantitative analysis of antidepressant drugs market. The market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

Key Findings of the Report:

In terms of revenue, global antidepressant drugs market was valued at US$ 24148.76 Mn in 2019 and is anticipated to grow at a CAGR of 12.13% over the forecast period (2021 – 2030).
Tablets and capsules accounted for a considerable share in the global antidepressant drugs market in 2019. The ease of administration, coupled with the reduced cost of packaging and delivery, is a major reason for this. Zoloft by Pfizer Inc., for instance, is an antidepressant drug that is available in the form of 25, 50, and 100 mg tablet.
The APAC region is expected to show the highest growth during the forecast years (2021 – 2030) in the global antidepressants drugs market. The rise in awareness by government bodies in the APAC countries is reducing the stigma associated with depression, and more individuals are seeking medical help.
Some of the players operating in the antidepressant drugs market are Abbot, AbbVie, AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., H. Lundbeck A/S, Janssen Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., sanofi-aventis U.S. LLC, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, amongst others.
Global Antidepressant Drugs Market:

By Type
Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)
Selective Serotonin Reuptake Inhibitors (SSRIs)
Tricyclic Antidepressants (TCAs)
Monoamine Oxidase Inhibitors (MAOIs)
Noradrenaline and Specific Serotoninergic Antidepressants (NASSAs)
By Mode of Administration
Tablets and Capsules
Liquids
Injections
Inhalation
Others
By End-Users
Hospitals and Clinics
Pharmacies
Urgent Care Centers
Research Institutes
Others
By Disorder Type
Major and Minor Depression
Obsessive Compulsive Disorder
Generalized Anxiety
Posttraumatic Stress (PTSD)
Social Anxiety
Agitation and Stress
Bipolar Disorder
Others
By Region
North America
U.S
Canada
Mexico
Rest of North America
Europe
France
The UK
Spain
Germany
Italy
Nordic Countries
Denmark
Finland
Iceland
Sweden
Norway
Benelux Union
Belgium
The Netherlands
Luxembourg
Rest of Europe
Asia Pacific
China
Japan
India
New Zealand
Australia
South Korea
Southeast Asia
Indonesia
Thailand
Malaysia
Singapore
Rest of Southeast Asia
Rest of Asia Pacific
Middle East and Africa
Saudi Arabia
UAE
Egypt
Kuwait
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Contact Us:
Company: Absolute Markets Insights
Email id: [email protected]
Phone: +91-740-024-2424
Contact Name: Shreyas Tanna
Website: https://www.absolutemarketsinsights.com